The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
about
Targeting survivin in cancer therapyVirotherapy against malignant glioma stem cellsHigh mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatmentA conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effectIntratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model.Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector.Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoterTargeting pediatric cancer stem cells with oncolytic virotherapyToward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cellsCancer stem cells: the final frontier for glioma virotherapy.Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Gene Therapies for Cancer: Strategies, Challenges and Successes.Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategyA Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy.Gene therapy of benign gynecological diseases.Promoters with cancer cell-specific activity for melanoma gene therapy.A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumorsOncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cellsTherapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct.Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton ratsAdenoviral virotherapy for malignant brain tumorsTherapeutic nanomedicine for brain cancer.Stem cells as delivery vehicles for oncolytic adenoviral virotherapy.Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.Oncolytic viral therapy of malignant gliomaViral-based gene delivery and regulated gene expression for targeted cancer therapy.Targeted Nanotechnology in Glioblastoma Multiforme.Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer.Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.Enhancing Adenoviral-Mediated Gene Transfer and Expression to Endometrial Cells.Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes.hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study.Cancer Terminator Viruses (CTV): A Better Solution for Viral-Based Therapy of Cancer.
P2860
Q28273083-BB1C2304-DE3A-436C-9C0F-E70E5FF7C208Q33665530-0941D824-2DC8-4C6E-B8E3-FDD40F85E2C8Q33713725-49B69F27-02B1-4FFF-8627-980FA9D98CFCQ34008026-3AAFA69E-3900-4198-8DED-609E64D21C50Q34042354-91DC5C65-F502-40AA-A928-A5DB84C7E40FQ34134426-6F4ADE9F-C377-494C-9336-119EEFC99CEDQ34221639-DC368699-B00C-4796-B085-40272C600C4CQ34262327-6365D588-E113-4BA2-9D46-D3D58C43EEC5Q34314771-7F289D63-4F16-48AC-8F6D-27F0A9D5271DQ34516701-2D8EEC12-399D-4A47-9514-CEE1B8A5A4E7Q35142325-B718DF7E-D3C1-4F0F-A629-F3F0BEB6B322Q35186312-35C34E60-1000-4C9F-9DF3-C0AFAEF88F15Q35190027-4A625F3F-6E85-4485-9CA6-D9189F8588B0Q35371213-3FA3EEA6-0D0A-4B39-985A-E2AE9F5C1F7AQ35620945-D8B759F9-316B-4538-87E6-E70CAD9B689FQ35770271-4C553EB1-75D1-4209-840F-EC6988ED2764Q35944371-998B7AD1-3BE0-4245-803B-9E8AEDFD77E3Q36367252-29EB32E2-845D-495E-803B-4F477CB22145Q36634430-E2E5A68C-2AE5-4CEF-AFE8-B3566C849598Q36909502-5AB31218-320E-437B-AA98-F24B8F7BBE1EQ36984046-B8A76D4D-5024-458E-9551-72494BC683ECQ37132217-449919B4-B0A9-469B-8EC9-118EA21C4CEEQ37223846-E43080BC-154E-48D8-AB93-5FFDF35ACA12Q37338427-94A52BA6-0F4E-4674-AE0A-18828821231FQ37466041-C30FF3CD-1AE8-493F-B5B5-F65DA5D42C16Q37467122-5B99CC92-AA2D-43B8-AC41-AA1F64407BAAQ37475446-BFE7A28D-0197-44C2-946A-B82B552370ECQ37533665-FD87015F-A1AF-463F-965E-7222774721D4Q37641366-6C1380BE-3D00-4199-9E72-5DAB40891367Q37730943-56F9480A-8CA7-4DCB-8CC3-BCF5769C3297Q39181862-C36ECDA9-3E1D-4650-8BCA-4D70BAFD98BFQ39543320-6C826E8B-6620-429D-A866-FE40AEBDF038Q39789577-2F41CE71-BC10-4A8E-B277-6088AA1D8DABQ40006009-A71947C7-8589-4759-AB94-6E0DD4915FBDQ40057137-EF4E2878-D89C-423D-9E0E-10883407E6D4Q42413644-054EE998-323E-47DD-8C02-E4E3EDA965C5Q47560447-CB35C66A-4432-4201-B209-E3172454D5DF
P2860
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The human survivin promoter: a ...... ategy for treatment of glioma.
@en
type
label
The human survivin promoter: a ...... ategy for treatment of glioma.
@en
prefLabel
The human survivin promoter: a ...... ategy for treatment of glioma.
@en
P2093
P1476
The human survivin promoter: a ...... ategy for treatment of glioma.
@en
P2093
Angel A Rivera
Clemens M F Dirven
Daniel Rein
Ilya V Ulasov
Maciej S Lesniak
Martine L M Lamfers
Minghui Wang
Winan J Van Houdt
Yosef S Haviv
P304
P356
10.3171/JNS.2006.104.4.583
P407
P577
2006-04-01T00:00:00Z